In a significant development that is expected to change the IT landscape <br />of Andhra Pradesh, IT Minister Nara Lokesh today signed a Memorandum of Understanding (MoU) with the ANSR, a global ...

The luxury cruise liner M.V. Empress arrived at the Visakhapatnam International Cruise Terminal here today, marking a significant milestone in the city’s advent as a premier destination for Cruise ...

Biocon Biologics has received Health Canada's approval for Yesafili, a biosimilar injection for eye ailments. As the first Eylea biosimilar approved in Canada, Yesafili's launch is set for July 4, ...

Bengaluru: Biocon Biologics Ltd., a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., has announced that Health Canada has granted a Notice of Compliance (NOC) for Yesafili ...

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch scheduled for July 4, 2025, targeting treatment of serious eye diseases.

Biocon has scrapped its plans to introduce generic versions of Novo Nordisk's Ozempic and Wegovy in China, citing intense local competition. The decision comes as numerous Chinese drugmakers are ...

Biocon Biologics receives Health Canada approval for its biosimilar Yesafili injection, used to treat various eye ailments. Launch is scheduled for July 4, 2025.

Biocon Biologics Ltd. (BBL), announced that Health Canada has granted a Notice of Compliance (NOC) for Yesafili (aflibercept), a biosimilar to Eylea injection, in vial and prefilled syringe ...

Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd. , said:“The approval of YESAFILI by Health Canada-the first biosimilar to EYLEA® in Canada-is a proud moment for Biocon Biologics.

Ramy Ayad, Head of Canada at Biocon Biologics, stated: “This is a significant achievement for Biocon Biologics in Canada. With the approval of YESAFILI, we are delivering on our promise to improve ...

Indian drugmaker Biocon has abandoned plans to market generic versions of Novo Nordisk’s hot-selling diabetes and weight-loss drugs in China due to local competition, a senior executive said.